BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Updates in Use of ARIs and Ra-223 for Metastatic Castration-Resistant Prostate Cancer

Case Based Peer Perspectives

Video Series

PEACE-3 Study Results: Study Population & Disposition

Please review the design and objectives of the phase 3 PEACE 3 study of ENZA + Ra-223 for ARPI-naïve mCRPC.

Videos

An expert discusses the latest advancements in the use of androgen receptor inhibitors (ARIs) and radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer, highlighting their evolving roles in improving patient outcomes.

An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after treatment with androgen receptor pathway inhibitors (ARPI) and docetaxel for localized prostate cancer.

Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate cancer, such as abiraterone (ABI) based on COU-AA-301 and enzalutamide (ENZA) based on AFFIRM.

Therapeutic options for a patient with mCRPC after ADT + docetaxel

An expert discusses the design and objectives of the PEACE-3 study, which investigates the combination of enzalutamide and radium-223 for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).

PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

An expert discusses the design and objectives of the Phase 3 PEACE-3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).

An expert discusses the key efficacy findings from the PEACE-3 study, including results on radiographic progression-free survival (rPFS) and overall survival (OS), and offers insights on how to interpret and apply these results in clinical practice.

PEACE-3 Study Results: Efficacy

An expert discusses the safety findings from the PEACE-3 study, highlighting the adverse events associated with the combination of enzalutamide and radium-223 in ARPI-naïve metastatic castration-resistant prostate cancer.

PEACE-3 Study Results: Safety

An expert discusses alternative treatment options for a symptomatic patient with metastatic castration-resistant prostate cancer (mCRPC) and highlights the caveats around the data from the Phase 3 ALSYMPCA study of radium-223, including its conduct in an era prior to the introduction of abiraterone (ABI) and enzalutamide (ENZA).

How would therapeutic options change if this patient was asymptomatic?

An expert discusses what has been learned about the use of bone-protecting agents and bone density scans for patients receiving an androgen receptor pathway inhibitor (ARPI) in combination with radium-223, based on data from the Phase 3 PEACE-3 study (Enza + Ra-223) and the Phase 3 ERA-223 study (AAP + Ra-223).

Protecting bone health for patients receiving Ra-223 + ARPI combination

An expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.

Ongoing studies of Ra-223–based combinations

Ongoing studies of Ra- 223–based combinations

PEACE-3 Study Results: Study Population & Disposition

EP: 1.Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP: 2.Therapeutic options for a patient with mCRPC after ADT + docetaxel

EP: 3.PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

EP: 4.PEACE-3 Study Results: Study Population & Disposition

EP: 5.PEACE-3 Study Results: Efficacy

EP: 6.PEACE-3 Study Results: Safety

EP: 7.How would therapeutic options change if this patient was asymptomatic?

EP: 8.Protecting bone health for patients receiving Ra-223 + ARPI combination

EP: 9.Ongoing studies of Ra-223–based combinations

EP: 10.Ongoing studies of Ra- 223–based combinations